INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2017

Once-weekly semaglutide reduced daily ad libitum energy intake by 24% and reduced body weight by 5.0 kg over 12 weeks in subjects with obesity.

In a randomised, double-blind, placebo-controlled crossover trial, 30 subjects with obesity received 12 weeks of once-weekly subcutaneous semaglutide (dose-escalated to 1.0 mg) or placebo. Semaglutide led to a lower ad libitum energy intake during lunch (-1255 kJ; P < .0001), the evening meal (P = .0401), and snacks (P = .0034), producing a 24% reduction in total daily ad libitum energy intake (-3036 kJ; P < .0001). Semaglutide also improved fasting appetite suppression scores, reduced hunger, cravings, and preference for high-fat foods, and reduced mean body weight by 5.0 kg predominantly from fat mass, with no difference in lean-mass-adjusted resting metabolic rate.

Study type
Randomised, double-blind, placebo-controlled crossover trial
Who was studied
30 subjects with obesity
What was measured
Ad libitum energy intake, appetite ratings, control of eating, food preference, resting metabolic rate, body weight, and body composition

THE PAPER

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Diabetes Obes Metab, 2017.

PubMed 28266779 ↗DOI 10.1111/dom.12932 ↗

Nutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.